Montelukast Viatris (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 and related mediators from binding. This inhibition reduces airway smooth‑muscle contraction, vascular leakage, and inflammatory cell recruitment, thereby decreasing bronchoconstriction and inflammation that underlie asthma and allergic airway disease.

The appropriate dose is determined by the prescribing healthcare professional based on the patient’s age, weight, and specific clinical condition. Physicians select the regimen that best matches the individual’s therapeutic needs and adjust it as necessary during follow‑up.

Safety data for Montelukast in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. While inhaled steroids directly reduce airway inflammation, montelukast targets leukotriene‑mediated pathways and is useful for patients who prefer oral therapy or have specific indications such as exercise‑induced bronchoconstriction. Choice of therapy depends on disease severity, patient preference and physician assessment.

Montelukast Viatris should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in humid or excessively hot environments, and keep out of reach of children.

The medication is taken orally, usually as a tablet swallowed whole with water. It is typically taken once daily, with or without food, as directed by the prescribing clinician. Consistent timing each day helps maintain steady drug levels.

Serious adverse events include allergic reactions such as rash, angioedema or anaphylaxis, and neuropsychiatric effects like depression, anxiety, or suicidal thoughts. Rare but severe complications may involve liver enzyme elevation, eosinophilic granulomatosis with polyangiitis, and severe skin reactions (e.g., Stevens‑Johnson syndrome). Patients should seek immediate medical attention if any of these occur.

Montelukast is contraindicated in individuals with known hypersensitivity to montelukast sodium or any of the tablet’s excipients. Caution is advised for patients with severe hepatic impairment, and clinicians should evaluate the risk‑benefit ratio before prescribing to such individuals.